Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.
Speaking at a Jefferies fireside chat with biotech analyst Amin Makarem, Brady described Aldeyra as an immunology company with a pipeline that began in front-of-the-eye diseases, including dry eye disease and allergic conjunctivitis. He said reproxalap remains an NDA-stage product and is the company’s primary near-term focus.
